Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Study Details
Study Description
Brief Summary
This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which patients are most likely to respond to the combination of trastuzumab and pertuzumab when given prior to surgery.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This study will evaluate for the first time the correlation between early changes in SUV and pCR in men and women with ER-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving trastuzumab and pertuzumab (PT) pre-operatively. This has not previously been evaluated in patients receiving anti HER2 therapy alone and as such is novel and potentially practice changing. The results from this phase 2 biomarker study will be used to plan a randomized study using a predefined cut point for SUV decline such that the investigators can further attempt to identify a group of individuals with HER2-positive early breast cancer who do not require cytotoxic chemotherapy in addition to anti-HER2 agents. This non-invasive biomarker approach will be of great interest to breast cancer oncologists and patients by facilitating a personalized approach to managing patients with HER2-positive disease that will undoubtedly spare toxicity and reduce the costs associated with anti-cancer strategies, without compromising efficacy.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Trastuzumab and Pertuzumab Preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET) |
Procedure: Positron emission tomography (PET)
PET will be performed at baseline and on day 15
Other Names:
Drug: Trastuzumab
8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
Other Names:
Drug: Pertuzumab
840 mg as a loading dose, then 420 mg every 3 weeks, IV
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Percent Change in Standardized Uptake Value (SUV) as Measured by SULmax on [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) [Baseline and Day 15]
SULmax is the maximum SUV corrected for lean body mass. Change in SULmax from baseline to Day 15 on FDG PET in correlation with pathological complete response (pCR) in patients treated with preoperative pertuzumab/trastuzumab. pCR was defined as no viable invasive cancer in breast and axilla by local pathology review. SULmax was measured via spherical volume over the target primary breast cancer tissue.
Secondary Outcome Measures
- Change in ptDNA With Response [3 months]
To correlate PIK3CA mutation status and other genomic alterations (mutations/somatic rearrangements) qualitatively and quantitatively in plasma tumor DNA (ptDNA) with pCR
- Change in PI3K Pathway Activation With Response [3 months]
To correlate PI3K pathway activation (e.g. PTEN low and/or PIK3CA mutation, human epidermal growth factor receptor (HER) 1-4 expression and/or phosphorylation) in tumor samples and pCR
- Changes in Ki67 With Response [3 months]
To correlate baseline and change (day 15) in Ki67 with pCR
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Female and male patients, 18 years old or older
-
Histologically proven infiltrating carcinoma of the breast on core needle biopsy that is: estrogen receptor (ER)/progesterone receptor (PR) ≤10% staining by immunohistochemistry (IHC) and HER2 positive - IHC 3+, in situ hybridization (ISH) ≥2.0, or average HER2 copy number ≥6.0 signals per cell or per current American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) or National Comprehensive Cancer Network (NCCN) guidelines. Note: All histological diagnostic material should be reviewed at enrolling institution as required per local standards.
-
Unresected, untreated breast cancer that meets one of the following clinical stages (see Appendix A): T2, T3, or T4a-c lesion, any N, M0. Note: Patients with inflammatory breast cancer (T4d) are not eligible. Bilateral cancers are permitted with approval of the Protocol Chair.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Appendix B)
-
Adequate organ function as follows:
-
Absolute neutrophil count (ANC) ≥ 1,500/mm3
-
Platelet count ≥ 100,000/mm3
-
Hemoglobin ≥ 10 g/dL
-
Creatinine ≤ 1.5 times the upper limit of normal with creatinine clearance ≥ 50 mL/min using the Modified Cockcroft-Gault method
-
Bilirubin (total) ≤ 1.5 times upper limit normal (with exception of Gilberts syndrome)
-
AST(SGOT), ALT(SGPT), and alkaline phosphatase ≤ 2 times the upper limit of normal
-
Adequate cardiac function as defined by left ventricular ejection fraction (LVEF) ≥ 50% on echocardiogram or multi-gated acquisition scan (MUGA)
-
Able and amenable to baseline and follow-up PET/CT imaging and study-specific biopsy procedures. Note: If there are any imaging concerns that the patient may not be suitable for quantitative PET/CT (e.g., a metallic device directly overlies the breast), discussion with the local and central radiologists is required to confirm eligibility for the trial. Also, it is expected that subjects have all PET/CT imaging done on pre-qualified machines for the study; if baseline imaging done on another machine, please contact the Protocol Chair/designee for guidance prior to confirming eligibility.
-
The patient, if of childbearing potential, is willing to use effective, non-hormonal contraception while on treatment and for at least 6 months following the last dose of therapy.
-
Patient understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form.
Exclusion Criteria:
-
Received prior or ongoing local (e.g radiation) or systemic treatment (chemotherapy or endocrine therapy) for the current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included as long as the patient has discontinued the treatment at least one month prior to baseline study biopsy.
-
Systemic treatment for prior cancer within the last 5 years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.
-
Women who are pregnant or nursing
-
Current use of any investigational agents
-
Known hypersensitivity to trastuzumab or pertuzumab
-
Any medical condition that in the opinion of the investigator puts the patient at risk of potentially serious complications while on this therapy. Specifically, uncontrolled hypertension (systolic >150 and/or diastolic >100), unstable angina, congestive heart failure of any New York Heart Association (NYHA) classification, serious cardiac arrhythmia requiring treatment (exception: atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within 6 months of enrollment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Alabama Comprehensive Cancer Center | Birmingham | Alabama | United States | 35294 |
| 2 | Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital | Washington | District of Columbia | United States | 20016 |
| 3 | Indiana University Simon Cancer Center | Indianapolis | Indiana | United States | 46202 |
| 4 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | United States | 21287-0013 |
| 5 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
| 6 | Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | United States | 27599 |
| 7 | Vanderbilt University | Nashville | Tennessee | United States | 37232 |
| 8 | Baylor College of Medicine | Houston | Texas | United States | 77030 |
| 9 | The University of Texas MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
| 10 | Fred Hutchinson Cancer Research Center - University of Washington | Seattle | Washington | United States | 98109 |
Sponsors and Collaborators
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Translational Breast Cancer Research Consortium
- Genentech, Inc.
Investigators
- Study Chair: Roisin Connolly, MBBCh, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Documents (Full-Text)
More Information
Publications
None provided.- TBCRC 026
- TBCRC026
- NA_00080994
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Trastuzumab and Pertuzumab |
|---|---|
| Arm/Group Description | Preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET) Positron emission tomography (PET): PET will be performed at baseline and on day 15 Trastuzumab: 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Pertuzumab: 840 mg as a loading dose, then 420 mg every 3 weeks, IV |
| Period Title: Overall Study | |
| STARTED | 88 |
| COMPLETED | 75 |
| NOT COMPLETED | 13 |
Baseline Characteristics
| Arm/Group Title | Trastuzumab and Pertuzumab |
|---|---|
| Arm/Group Description | Preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET) Positron emission tomography (PET): PET will be performed at baseline and on day 15 Trastuzumab: 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Pertuzumab: 840 mg as a loading dose, then 420 mg every 3 weeks, IV |
| Overall Participants | 88 |
| Age (years) [Median (Standard Deviation) ] | |
| Median (Standard Deviation) [years] |
58
(12.6)
|
| Sex: Female, Male (Count of Participants) | |
| Female |
88
100%
|
| Male |
0
0%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |
| Hispanic or Latino |
5
5.7%
|
| Not Hispanic or Latino |
79
89.8%
|
| Unknown or Not Reported |
4
4.5%
|
| Race/Ethnicity, Customized (Count of Participants) | |
| White |
75
85.2%
|
| Black or African American |
7
8%
|
| Other |
6
6.8%
|
| Region of Enrollment (Count of Participants) | |
| United States |
88
100%
|
| Eastern Cooperative Oncology Group (ECOG) Performance Status (Count of Participants) | |
| 0 |
76
86.4%
|
| 1 |
12
13.6%
|
| Baseline clinical tumor size (cm) [Median (Standard Deviation) ] | |
| Median (Standard Deviation) [cm] |
3.7
(2)
|
| Clinical tumor T staging (Count of Participants) | |
| T1 |
0
0%
|
| T2 |
66
75%
|
| T3 |
19
21.6%
|
| T4 |
3
3.4%
|
| Baseline clinical nodal status (Count of Participants) | |
| Negative |
45
51.1%
|
| Positive |
43
48.9%
|
| Clinical tumor N staging (Count of Participants) | |
| N0 |
45
51.1%
|
| N1 |
38
43.2%
|
| N2 |
3
3.4%
|
| N3 |
2
2.3%
|
| Baseline clinical stage (Count of Participants) | |
| Stage I |
0
0%
|
| Stage II |
74
84.1%
|
| Stage III |
14
15.9%
|
| Stage IV |
0
0%
|
| Tumor Grade (Count of Participants) | |
| Grade 1 |
0
0%
|
| Grade 2 |
22
25%
|
| Grade 3 |
66
75%
|
| Additional neoadjuvant therapy (Count of Participants) | |
| Yes |
25
28.4%
|
| No |
59
67%
|
| N/A |
4
4.5%
|
| Type of Surgery (Count of Participants) | |
| Mastectomy |
51
58%
|
| Breast-conserving therapy |
33
37.5%
|
| N/A |
4
4.5%
|
Outcome Measures
| Title | Percent Change in Standardized Uptake Value (SUV) as Measured by SULmax on [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) |
|---|---|
| Description | SULmax is the maximum SUV corrected for lean body mass. Change in SULmax from baseline to Day 15 on FDG PET in correlation with pathological complete response (pCR) in patients treated with preoperative pertuzumab/trastuzumab. pCR was defined as no viable invasive cancer in breast and axilla by local pathology review. SULmax was measured via spherical volume over the target primary breast cancer tissue. |
| Time Frame | Baseline and Day 15 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Data was evaluable in only 83/88 participants. |
| Arm/Group Title | Trastuzumab and Pertuzumab |
|---|---|
| Arm/Group Description | Preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET) Positron emission tomography (PET): PET will be performed at baseline and on day 15 Trastuzumab: 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Pertuzumab: 840 mg as a loading dose, then 420 mg every 3 weeks, IV |
| Measure Participants | 83 |
| pCR |
61.9
(22.3)
|
| no pCR |
34.3
(31.9)
|
| Title | Change in ptDNA With Response |
|---|---|
| Description | To correlate PIK3CA mutation status and other genomic alterations (mutations/somatic rearrangements) qualitatively and quantitatively in plasma tumor DNA (ptDNA) with pCR |
| Time Frame | 3 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change in PI3K Pathway Activation With Response |
|---|---|
| Description | To correlate PI3K pathway activation (e.g. PTEN low and/or PIK3CA mutation, human epidermal growth factor receptor (HER) 1-4 expression and/or phosphorylation) in tumor samples and pCR |
| Time Frame | 3 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Changes in Ki67 With Response |
|---|---|
| Description | To correlate baseline and change (day 15) in Ki67 with pCR |
| Time Frame | 3 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
Adverse Events
| Time Frame | Up to 16 weeks | |
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | Trastuzumab and Pertuzumab | |
| Arm/Group Description | Preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET) Positron emission tomography (PET): PET will be performed at baseline and on day 15 Trastuzumab: 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Pertuzumab: 840 mg as a loading dose, then 420 mg every 3 weeks, IV | |
All Cause Mortality |
||
| Trastuzumab and Pertuzumab | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/88 (0%) | |
Serious Adverse Events |
||
| Trastuzumab and Pertuzumab | ||
| Affected / at Risk (%) | # Events | |
| Total | 2/88 (2.3%) | |
| Gastrointestinal disorders | ||
| Enterocolitis | 1/88 (1.1%) | 1 |
| Injury, poisoning and procedural complications | ||
| Sepsis | 1/88 (1.1%) | 2 |
Other (Not Including Serious) Adverse Events |
||
| Trastuzumab and Pertuzumab | ||
| Affected / at Risk (%) | # Events | |
| Total | 88/88 (100%) | |
| Gastrointestinal disorders | ||
| Diarrhea | 80/88 (90.9%) | 80 |
| Dyspepsia | 5/88 (5.7%) | 5 |
| Mucositis | 12/88 (13.6%) | 12 |
| Nausea | 24/88 (27.3%) | 24 |
| General disorders | ||
| Fatigue | 30/88 (34.1%) | 30 |
| Chills | 10/88 (11.4%) | 10 |
| Nervous system disorders | ||
| Headache | 13/88 (14.8%) | 13 |
| Dysgeusia | 6/88 (6.8%) | 6 |
| Skin and subcutaneous tissue disorders | ||
| Rash (NOS) | 17/88 (19.3%) | 17 |
| Dry skin | 5/88 (5.7%) | 5 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Roisin Connolly |
|---|---|
| Organization | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Phone | (410) 614-9217 |
| rconnol2@jhmi.edu |
- TBCRC 026
- TBCRC026
- NA_00080994